Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system

BACKGROUND: Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients. Despite proven efficacy of the monoclonal antibodies, cardiovascular-induced adverse events such as heart failure, hypertension, ischemic he...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Jazairi, Abdulrazaq S., Bahammam, Nahlah, Aljuaid, Dhai, Almutairi, Lama, Alshahrani, Shroog, Albuhairan, Norah, Cahusac, Peter M. B., Korayem, Ghazwa B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519122/
https://www.ncbi.nlm.nih.gov/pubmed/37749652
http://dx.doi.org/10.1186/s40959-023-00184-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519122/
https://www.ncbi.nlm.nih.gov/pubmed/37749652
http://dx.doi.org/10.1186/s40959-023-00184-z

Ejemplares similares